Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Evaxion Biotech ( (EVAX) ).
Evaxion Biotech A/S announced amendments to its Articles of Association following the exercise of certain investor warrants, resulting in an increase in share capital. From October 15 to October 28, 2025, the company registered a total share capital increase of nominal DKK 4,735,475, raising the total share capital to DKK 103,783,939. This move, which involved the issuance of multiple ordinary shares over several days, reflects the company’s ongoing efforts to enhance its financial standing and operational capacity, potentially impacting its market position and shareholder value.
The most recent analyst rating on (EVAX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
Evaxion Biotech’s overall score is driven by strong technical indicators and positive developments from the earnings call, including R&D progress and financial stability. However, financial performance remains a concern due to ongoing losses and reliance on debt, impacting the valuation negatively.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion Biotech A/S is a company based in Denmark that specializes in developing advanced software for the creation of novel immune therapies and vaccines. The company operates under the names Evaxion Biotech A/S and NovVac A/S.
Average Trading Volume: 1,582,558
Technical Sentiment Signal: Hold
Current Market Cap: $36.32M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.